Mbiomics raises €13.0M Series A round

23 March 2023· Munich, Germany· health, biotech, ai, b2b, software_hardware

The funding is intended to build the company's microbiome profiling platform, accelerate the identification of lead drug candidates, expand R&D teams and facilities in Munich, and increase activities in the United States.

Investors

LeadMIG Capital
Also participating
High-Tech GründerfondsBayern KapitalGerman AcceleratorPrivate Seed Investors

About Mbiomics

Stage
Series A
Headquarters
Munich, Germany
Founded
2020
Team Size
21–50
Sectors
healthbiotechaib2bsoftware_hardware

Source: https://www.mig.ag/en/press-releases/mig-capital-leads-13-million-series-a-financing-of-microbiome-therapeutics-biotech-mbiomics/